Drug
CFI-402257
CFI-402257 is a pharmaceutical drug with 4 clinical trials. Currently 4 active trials ongoing.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
4(100%)
Phase Distribution
Ph phase_2
1
25%
Ph phase_1
3
75%
Phase Distribution
3
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
3(75.0%)
Phase 2Efficacy & side effects
1(25.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
4
trials recruiting
Total Trials
4
all time
Status Distribution
Active(4)
Detailed Status
Active, not recruiting3
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
4
Success Rate
N/A
Most Advanced
Phase 2
Trials by Phase
Phase 13 (75.0%)
Phase 21 (25.0%)
Trials by Status
recruiting125%
active_not_recruiting375%
Recent Activity
4 active trials
Showing 4 of 4
recruitingphase_2
Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer
NCT05601440
active_not_recruitingphase_1
CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer
NCT03568422
active_not_recruitingphase_1
CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer
NCT05251714
active_not_recruitingphase_1
A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid Tumors
NCT02792465
Clinical Trials (4)
Showing 4 of 4 trials
NCT05601440Phase 2
Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer
NCT03568422Phase 1
CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer
NCT05251714Phase 1
CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer
NCT02792465Phase 1
A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid Tumors
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4